Caribou Biosciences upgraded by Citigroup with a new price target
$CRBU
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup upgraded Caribou Biosciences from Neutral to Buy and set a new price target of $27.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2024 | $13.00 → $3.00 | Outperform → In-line | Evercore ISI |
| 11/8/2023 | Neutral | Cantor Fitzgerald | |
| 10/31/2023 | $13.00 | Outperform | Evercore ISI |
| 7/11/2023 | $23.00 | Buy | Truist |
| 2/18/2022 | $22.00 | Outperform | RBC Capital |
| 2/14/2022 | $19.00 | Buy | Brookline Capital |
| 12/1/2021 | $36.00 | Outperform | Oppenheimer |
| 11/30/2021 | $28.00 | Buy | H.C. Wainwright |
4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. But T-cell therapies also carry hard limits: they can be brutally toxic, they are often manufactured one p
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers -- -- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent -- -- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST -- BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient who previously received an anti-BCMA CAR-T showed an early complete response that was ongoing as of the data cutoff date -- -- EHA oral presentation scheduled for Sunday, June 14, 2026, at 11:00am CEST -- -- CaMMouflage phase 1 initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 -- BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical
Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously
Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral
Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00
8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
DEFA14A - Caribou Biosciences, Inc. (0001619856) (Filer)
4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med
SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)
SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)
SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)
First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22)86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient settingData highlight vispa-cel's potential as best-in-class allogeneic CAR-T cell therapy for LBCLConference c
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46